Phase 1b/2 RCT | Niraparib plus nivolumab vs. niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer.
20 Jul, 2022 | 11:39h | UTCNiraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/TheLancetOncol/status/1545362068026556418